Trial Profile
A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary) ; Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms API ADAD
- Sponsors Genentech
- 20 Jul 2023 Status changed from active, no longer recruiting to completed.
- 20 Jul 2023 Results assessing the safety and efficacy of the investigational product crenezumab presented at the Alzheimer's Association International Conference 2023
- 20 Jul 2023 Results comparing Impact of reference regions on longitudinal florbetapir PET SUVR changes from this study presented at the Alzheimer's Association International Conference 2023